Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Aly-Khan A. Lalani,Anand Swaminath,Gregory R. Pond,Anil Kapoor,William Chu,Jonathan L. Bramson,Michael G. Surette,Mark Levine,Sebastien J. Hotte

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

2020

Aly-Khan A. Lalani
Anand Swaminath
Gregory R. Pond
Anil Kapoor
William Chu
Jonathan L. Bramson
Michael G. Surette
Mark Levine
Sebastien J. Hotte

TPS761Background: Randomized data from the interferon era demonstrated modest survival benefits of cytoreductive nephrectomy (CN) in patients with advanced renal cell carcinoma (aRCC). Results from...

Keywords:

Nephrectomy
Oncology
Hypofractionated Radiotherapy
Ipilimumab
Pathology
Nivolumab
Renal cell carcinoma
Internal medicine
Medicine
Metastatic kidney cancer
in patient
cytoreductive nephrectomy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations